These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 20386529)

  • 1. Controversies in the design of phase II clinical trials.
    Seymour L
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):95-7. PubMed ID: 20386529
    [No Abstract]   [Full Text] [Related]  

  • 2. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 4. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 9. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
    Francart J; Legrand C; Sylvester R; Van Glabbeke M; van Meerbeeck JP; Robert A
    J Clin Oncol; 2006 Jul; 24(19):3007-12. PubMed ID: 16809726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive oxygen species may have antitumor activity in metastatic melanoma.
    Tuma RS
    J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
    [No Abstract]   [Full Text] [Related]  

  • 12. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASSENT-3: implications for future trial design and clinical practice.
    Van de Werf F
    Eur Heart J; 2002 Jun; 23(12):911-2. PubMed ID: 12069439
    [No Abstract]   [Full Text] [Related]  

  • 15. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
    Chabner BA; Ratain MJ
    Clin Cancer Res; 2007 Nov; 13(21):6540. PubMed ID: 17975169
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical studies--what is the putting of the question?].
    Guttenberger R
    Strahlenther Onkol; 1999 Apr; 175 Suppl 1():14-6. PubMed ID: 10230452
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creeping phase II-ism and the medical pharmaceutical complex: weapons of mass distraction in the war against lung cancer.
    Turrisi AT
    J Clin Oncol; 2005 Aug; 23(22):4827-9. PubMed ID: 15939926
    [No Abstract]   [Full Text] [Related]  

  • 19. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
    Francart J; Vaes E; Henrard S; Legrand C; Baas P; Gaafar R; van Meerbeeck JP; Sylvester R; Robert A
    Eur J Cancer; 2009 Sep; 45(13):2304-11. PubMed ID: 19502050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Pu YS; Vogelzang NJ
    BJU Int; 2008 Apr; 101(7):795-803. PubMed ID: 18070193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.